WKYT | Lexington, Kentucky | News

Lilly Alzheimer's drug trial yields promising sign

INDIANAPOLIS (AP) - Eli Lilly's potential Alzheimer's disease treatment failed to slow mental decline in two late-stage studies, but combined data from both trials showed promising results in patients with mild-to-moderate cases of the mind-robbing disease.

The Indianapolis drugmaker says pooled data from both studies showed a statistically significant slowing of cognitive or mental decline, as did a subgroup of patients with mild cases of the disease.

Lilly will discuss the results with regulators and plan the next steps for the drug, labeled solanezumab (sol-ah-NAYZ-uh-mab).

There is no cure for the illness that affects a person's memory and their ability to think. Current treatments only temporarily ease symptoms such as memory loss, confusion and agitation. They don't slow, stop or reverse mental decline.

Lilly's stock rose 3 percent to $43.75 in premarket trading.

(Copyright 2012 The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.)


Comments are posted from viewers like you and do not always reflect the views of this station.
powered by Disqus

WKYT

2851 Winchester Rd. Lexington, Ky 40509 859-299-0411 - switchboard 859-299-2727 - newsroom
Gray Television, Inc. - Copyright © 2002-2014 - Designed by Gray Digital Media - Powered by Clickability 167307745